Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment

  • 0Department of Gastroenterology, Hôtel-Dieu, 1 place du Parvis Notre Dame, 75181 Paris Cedex 4, France. agnes.fourmestraux@htd.ap-hop-paris.fr

|

|

Summary

This summary is machine-generated.

Complete remission of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is achieved in 79% of Helicobacter pylori-positive patients without lymph node involvement. This study identifies nodal status as a key predictor for lymphoma regression after H. pylori eradication.

Area Of Science

  • Gastroenterology
  • Oncology
  • Infectious Disease

Background

  • Gastric MALT lymphoma remission rates after H. pylori eradication vary widely (41-100%).
  • Predictive factors for gastric lymphoma regression post-treatment remain unclear.

Purpose Of The Study

  • To investigate discrepancies in remission rates for gastric MALT lymphoma.
  • To identify predictors of gastric lymphoma regression following H. pylori eradication therapy.

Main Methods

  • Prospective enrollment of 46 patients with localized gastric MALT lymphoma (Ann Arbor stages I(E), II(E)).
  • Assessment of H. pylori status via histology, culture, PCR, and serology.
  • Endoscopic ultrasonography for staging and follow-up examinations every four months.

Main Results

  • Complete histological regression observed in 43% (19/44) of patients.
  • No regression in H. pylori-negative patients.
  • In H. pylori-positive patients, regression increased from 56% to 79% when nodal involvement was absent (p<0.0001).

Conclusions

  • Absence of nodal involvement is the sole predictive factor for regression in gastric MALT lymphoma.
  • Complete remission (79%) is achievable in H. pylori-positive patients with localized disease and no nodal involvement.

Related Concept Videos